Quintanilha, Julia C.F.
Sibley, Alexander B.
Liu, Yingmiao
Niedzwiecki, Donna
Halabi, Susan
Rogers, Layne
O’Neil, Bert
Kindler, Hedy
Kelly, William
Venook, Alan
McLeod, Howard L.
Ratain, Mark J.
Nixon, Andrew B.
Innocenti, Federico
Owzar, Kouros
Article History
Received: 20 November 2023
Accepted: 25 April 2024
First Online: 14 May 2024
Declarations
:
: The analyses were conducted using clinical, protein marker and germline DNA genotyping data from patients registered to CALGB/SWOG 80405 (registered under National Clinical Trial number NCT00265850) who had consented to participation in Institutional Review Board (IRB) approved pharmacogenomic substudy (CALGB 60501). The germline DNA and clinical data used in the validation analyses were obtained from patients from CALGB 90401 (NCT00110214) and CALGB 80303 (NCT00088894) who had provided consent to research under IRB approved pharmacogenomic substudies (CALGB 60404 and CALGB 60401 respectively). CALGB/SWOG 80405, CALGB 90401 and CALGB 80303 were multi-center clinical trials. Each of these three substudies were approved by the Cancer Treatment Evaluation Program (CTEP) of the National Cancer Institute (NCI) and the Institutional Review Board (IRB) of each participating center. The analyses presented in this paper were conducted under protocol Pro00113199 approved by the Duke Health IRB of Duke University.
: Not applicable.
: A.B.N. has received industry funding from Genentech, Genmab, MedImmune/AstraZeneca, and Seattle Genetics and received personal fees from Leap Therapeutics; F.I. is a BeiGene employee and holds stocks in AbbVie and BeiGene; J.C.F.Q. is an employee of Foundation Medicine, a wholly-owned subsidiary of Roche, and has equity interest in Roche; S.H. serves on data monitoring committees for AVEO, BMS, Janssen and Sanofi, and has received research funding from ASCO and Astellas; The remaining authors declare no competing interests.